158 related articles for article (PubMed ID: 31908413)
21. Valproic Acid Decreases Endothelial Colony Forming Cells Differentiation and Induces Endothelial-to-Mesenchymal Transition-like Process.
Nevo N; Lecourt S; Bièche I; Kucia M; Cras A; Blandinieres A; Vacher S; Gendron N; Guerin CL; Ratajczak MZ; Smadja DM
Stem Cell Rev Rep; 2020 Apr; 16(2):357-368. PubMed ID: 31898801
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
23. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).
Zhu Y; Liu C; Cui Y; Nadiminty N; Lou W; Gao AC
Prostate; 2014 Aug; 74(11):1086-94. PubMed ID: 24819501
[TBL] [Abstract][Full Text] [Related]
25. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Waaga-Gasser A; Haferkamp A; Blaheta RA
BMC Cancer; 2011 Aug; 11():375. PubMed ID: 21867506
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Sidana A; Wang M; Shabbeer S; Chowdhury WH; Netto G; Lupold SE; Carducci M; Rodriguez R
J Biomed Biotechnol; 2012; 2012():180363. PubMed ID: 23093837
[TBL] [Abstract][Full Text] [Related]
28. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.
Wright ME; Tsai MJ; Aebersold R
Mol Endocrinol; 2003 Sep; 17(9):1726-37. PubMed ID: 12775765
[TBL] [Abstract][Full Text] [Related]
30. The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.
Tran LNK; Kichenadasse G; Butler LM; Centenera MM; Morel KL; Ormsby RJ; Michael MZ; Lower KM; Sykes PJ
Mol Cancer Ther; 2017 Dec; 16(12):2689-2700. PubMed ID: 28802253
[TBL] [Abstract][Full Text] [Related]
31. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors.
Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS
J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945
[TBL] [Abstract][Full Text] [Related]
32. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
33. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.
Morell C; Bort A; Vara D; Ramos-Torres A; Rodríguez-Henche N; Díaz-Laviada I
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):248-57. PubMed ID: 27324222
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Venkataramani V; Rossner C; Iffland L; Schweyer S; Tamboli IY; Walter J; Wirths O; Bayer TA
J Biol Chem; 2010 Apr; 285(14):10678-89. PubMed ID: 20145244
[TBL] [Abstract][Full Text] [Related]
35. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
36. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
37. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment.
Stettner M; Kaulfuss S; Burfeind P; Schweyer S; Strauss A; Ringert RH; Thelen P
Mol Cancer Ther; 2007 Oct; 6(10):2626-33. PubMed ID: 17913855
[TBL] [Abstract][Full Text] [Related]
38. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
[TBL] [Abstract][Full Text] [Related]
39. HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers.
Vulcano F; Ciccarelli C; Mattia G; Marampon F; Giampiero M; Milazzo L; Pascuccio M; Zani BM; Giampaolo A; Hassan HJ
Exp Cell Res; 2006 May; 312(9):1590-7. PubMed ID: 16739251
[TBL] [Abstract][Full Text] [Related]
40. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
